MP57-08 PROSTATE-SPECIFIC ANTIGEN DENSITY IS THE MOST APPROPRIATE FACTOR FOR DETECTING UNFAVORABLE PATHOLOGY AFTER RADICAL PROSTATECTOMY IN MEN ELIGIBLE FOR ACTIVE SURVEILLANCE FROM MUTLI-INSTITUTIONAL STUDY Article Swipe

PDF

Takahiro Inoue , Kei Mizuno , Hidefumi Kinoshita , Toshifumi Yano , Hiroaki Kawanishi , Hideki Kanda , Naoki Terada , Tomomi Kamba , Kazuhiro Okumura , Mutsushi Kawakita , Keiji Ogura , Yoshiki Sugimura , Tadashi Matsuda , Osamu Ogawa ·

YOU? · · 2016 · Open Access · · DOI: https://doi.org/10.1016/j.juro.2016.02.662

You have accessJournal of UrologyProstate Cancer: Localized: Surgical Therapy III1 Apr 2016MP57-08 PROSTATE-SPECIFIC ANTIGEN DENSITY IS THE MOST APPROPRIATE FACTOR FOR DETECTING UNFAVORABLE PATHOLOGY AFTER RADICAL PROSTATECTOMY IN MEN ELIGIBLE FOR ACTIVE SURVEILLANCE FROM MUTLI-INSTITUTIONAL STUDY Takahiro Inoue, Kei Mizuno, Hidefumi Kinoshita, Toshifumi Yano, Hiroaki Kawanishi, Hideki Kanda, Naoki Terada, Tomomi Kamba, Kazuhiro Okumura, Mutsushi Kawakita, Keiji Ogura, Yoshiki Sugimura, Tadashi Matsuda, and Osamu Ogawa Takahiro InoueTakahiro Inoue More articles by this author , Kei MizunoKei Mizuno More articles by this author , Hidefumi KinoshitaHidefumi Kinoshita More articles by this author , Toshifumi YanoToshifumi Yano More articles by this author , Hiroaki KawanishiHiroaki Kawanishi More articles by this author , Hideki KandaHideki Kanda More articles by this author , Naoki TeradaNaoki Terada More articles by this author , Tomomi KambaTomomi Kamba More articles by this author , Kazuhiro OkumuraKazuhiro Okumura More articles by this author , Mutsushi KawakitaMutsushi Kawakita More articles by this author , Keiji OguraKeiji Ogura More articles by this author , Yoshiki SugimuraYoshiki Sugimura More articles by this author , Tadashi MatsudaTadashi Matsuda More articles by this author , and Osamu OgawaOsamu Ogawa More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2016.02.662AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Most of low risk prostate cancer would not become life-threatening during lifetime. Active surveillance (AS) has emerged as an alternative to immediate treatment for those men, but the consensus in defining appropriate candidates is still lacking. We analyzed preoperative factors that predict upstaging (≥ pT3) or upgrading (radical prostatectomy (RP) Gleason score ≥ 7), defined as ′reclassification′, and also factors that detect pathological stage ≥ pT3 or RP Gleason score ≥ 4+3, defined as ′adverse pathology′ in AS candidates by examining the pathological findings of RP specimens. METHODS The retrospective study consisted of 1753 men who underwent RP at six independent high volume centers from 2005 to 2011. Of these patients, 306 met the AS criteria that included clinical stage T1c/T2 disease, serum PSA ≤ 10 ng/ml, Gleason score ≤ 6, and ≤ 2 positive cores. The clinic-pathological features were compared between patients with and without ′reclassification′ and ′adverse pathology′ after RP. RESULTS Among them, 167 (54.6%) required disease reclassification, and 42 (13.7%) had adverse pathology. Preoperative parameters evaluated included age, PSA, PSA density (PSAD), and number and percentage of positive cores. On multivariate analysis, age, PSAD and percentage of positive cores (PPCs) were independently associated with disease reclassification (P = 0.0033, 0.0006 and 0.0001, respectively), and PSAD and PPCs were with adverse pathology (P = 0.0030 and 0.047, respectively). The rate of reclassification and adverse pathology was significantly higher among patients with less than 10-core biopsy than the others (63.2% vs. 46.6%, P = 0.004 and 27.8% vs. 14.9%, P = 0.007, respectively). Multivariate analysis of the cases with 10 or more biopsy cores revealed PSAD and PPCs were significant factors of disease reclassification (P = 0.016 and 0.0084, respectively), and, PSAD was that of adverse pathology (P = 0.034). CONCLUSIONS Because the rate of reclassification and adverse pathology was significantly higher among patients with less than 10-core biopsy than the others, appropriate number of biopsy cores are needed when selecting candidates for AS. Furthermore, preoperative PSAD was still the most important factor associated with unfavorable pathological feature of RP specimens even under different methods of examination of prostate volume among the institutions. © 2016FiguresReferencesRelatedDetails Volume 195Issue 4SApril 2016Page: e755-e756 Advertisement Copyright & Permissions© 2016MetricsAuthor Information Takahiro Inoue More articles by this author Kei Mizuno More articles by this author Hidefumi Kinoshita More articles by this author Toshifumi Yano More articles by this author Hiroaki Kawanishi More articles by this author Hideki Kanda More articles by this author Naoki Terada More articles by this author Tomomi Kamba More articles by this author Kazuhiro Okumura More articles by this author Mutsushi Kawakita More articles by this author Keiji Ogura More articles by this author Yoshiki Sugimura More articles by this author Tadashi Matsuda More articles by this author Osamu Ogawa More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...

Related Topics

Prostatectomy

Medicine

Gynaecology

Prostate-Specific Antigen

Concepts

Prostatectomy Medicine Prostate cancer Gynecology Prostate-specific antigen Urology General surgery Cancer Internal medicine

Metadata

Type: article
Language: en
Landing Page: https://doi.org/10.1016/j.juro.2016.02.662
PDF: https://www.auajournals.org/doi/pdf/10.1016/j.juro.2016.02.662
OA Status: bronze
Related Works: 10
OpenAlex ID: https://openalex.org/W2316247344

All OpenAlex metadata

Raw OpenAlex JSON

OpenAlex ID: https://openalex.org/W2316247344

Canonical identifier for this work in OpenAlex
DOI: https://doi.org/10.1016/j.juro.2016.02.662

Digital Object Identifier
Title: MP57-08 PROSTATE-SPECIFIC ANTIGEN DENSITY IS THE MOST APPROPRIATE FACTOR FOR DETECTING UNFAVORABLE PATHOLOGY AFTER RADICAL PROSTATECTOMY IN MEN ELIGIBLE FOR ACTIVE SURVEILLANCE FROM MUTLI-INSTITUTIONAL STUDY

Work title
Type: article

OpenAlex work type
Language: en

Primary language
Publication year: 2016

Year of publication
Publication date: 2016-03-28

Full publication date if available
Authors: Takahiro Inoue, Kei Mizuno, Hidefumi Kinoshita, Toshifumi Yano, Hiroaki Kawanishi, Hideki Kanda, Naoki Terada, Tomomi Kamba, Kazuhiro Okumura, Mutsushi Kawakita, Keiji Ogura, Yoshiki Sugimura, Tadashi Matsuda, Osamu Ogawa

List of authors in order
Landing page: https://doi.org/10.1016/j.juro.2016.02.662

Publisher landing page
PDF URL: https://www.auajournals.org/doi/pdf/10.1016/j.juro.2016.02.662

Direct link to full text PDF
Open access: Yes

Whether a free full text is available
OA status: bronze

Open access status per OpenAlex
OA URL: https://www.auajournals.org/doi/pdf/10.1016/j.juro.2016.02.662

Direct OA link when available
Concepts: Prostatectomy, Medicine, Prostate cancer, Gynecology, Prostate-specific antigen, Urology, General surgery, Cancer, Internal medicine

Top concepts (fields/topics) attached by OpenAlex
Cited by: 0

Total citation count in OpenAlex
Related works (count): 10

Other works algorithmically related by OpenAlex

Full payload

id	https://openalex.org/W2316247344
doi	https://doi.org/10.1016/j.juro.2016.02.662
ids.doi	https://doi.org/10.1016/j.juro.2016.02.662
ids.mag	2316247344
ids.openalex	https://openalex.org/W2316247344
fwci	0.0
type	article
title	MP57-08 PROSTATE-SPECIFIC ANTIGEN DENSITY IS THE MOST APPROPRIATE FACTOR FOR DETECTING UNFAVORABLE PATHOLOGY AFTER RADICAL PROSTATECTOMY IN MEN ELIGIBLE FOR ACTIVE SURVEILLANCE FROM MUTLI-INSTITUTIONAL STUDY
biblio.issue	4S
biblio.volume	195
biblio.last_page
biblio.first_page
topics[0].id	https://openalex.org/T10124
topics[0].field.id	https://openalex.org/fields/27
topics[0].field.display_name	Medicine
topics[0].score	0.9839000105857849
topics[0].domain.id	https://openalex.org/domains/4
topics[0].domain.display_name	Health Sciences
topics[0].subfield.id	https://openalex.org/subfields/2740
topics[0].subfield.display_name	Pulmonary and Respiratory Medicine
topics[0].display_name	Prostate Cancer Diagnosis and Treatment
topics[1].id	https://openalex.org/T10543
topics[1].field.id	https://openalex.org/fields/27
topics[1].field.display_name	Medicine
topics[1].score	0.9815000295639038
topics[1].domain.id	https://openalex.org/domains/4
topics[1].domain.display_name	Health Sciences
topics[1].subfield.id	https://openalex.org/subfields/2740
topics[1].subfield.display_name	Pulmonary and Respiratory Medicine
topics[1].display_name	Prostate Cancer Treatment and Research
topics[2].id	https://openalex.org/T11970
topics[2].field.id	https://openalex.org/fields/13
topics[2].field.display_name	Biochemistry, Genetics and Molecular Biology
topics[2].score	0.909500002861023
topics[2].domain.id	https://openalex.org/domains/1
topics[2].domain.display_name	Life Sciences
topics[2].subfield.id	https://openalex.org/subfields/1312
topics[2].subfield.display_name	Molecular Biology
topics[2].display_name	Molecular Biology Techniques and Applications
is_xpac	False
apc_list
apc_paid
concepts[0].id	https://openalex.org/C2779466945
concepts[0].level	4
concepts[0].score	0.8781982660293579
concepts[0].wikidata	https://www.wikidata.org/wiki/Q1765251
concepts[0].display_name	Prostatectomy
concepts[1].id	https://openalex.org/C71924100
concepts[1].level	0
concepts[1].score	0.819034218788147
concepts[1].wikidata	https://www.wikidata.org/wiki/Q11190
concepts[1].display_name	Medicine
concepts[2].id	https://openalex.org/C2780192828
concepts[2].level	3
concepts[2].score	0.7864266633987427
concepts[2].wikidata	https://www.wikidata.org/wiki/Q181257
concepts[2].display_name	Prostate cancer
concepts[3].id	https://openalex.org/C29456083
concepts[3].level	1
concepts[3].score	0.5157954692840576
concepts[3].wikidata	https://www.wikidata.org/wiki/Q1221899
concepts[3].display_name	Gynecology
concepts[4].id	https://openalex.org/C2781406297
concepts[4].level	4
concepts[4].score	0.4469529390335083
concepts[4].wikidata	https://www.wikidata.org/wiki/Q409450
concepts[4].display_name	Prostate-specific antigen
concepts[5].id	https://openalex.org/C126894567
concepts[5].level	1
concepts[5].score	0.3888070285320282
concepts[5].wikidata	https://www.wikidata.org/wiki/Q105650
concepts[5].display_name	Urology
concepts[6].id	https://openalex.org/C61434518
concepts[6].level	1
concepts[6].score	0.3578466773033142
concepts[6].wikidata	https://www.wikidata.org/wiki/Q932510
concepts[6].display_name	General surgery
concepts[7].id	https://openalex.org/C121608353
concepts[7].level	2
concepts[7].score	0.3353397846221924
concepts[7].wikidata	https://www.wikidata.org/wiki/Q12078
concepts[7].display_name	Cancer
concepts[8].id	https://openalex.org/C126322002
concepts[8].level	1
concepts[8].score	0.2792052626609802
concepts[8].wikidata	https://www.wikidata.org/wiki/Q11180
concepts[8].display_name	Internal medicine
keywords[0].id	https://openalex.org/keywords/prostatectomy
keywords[0].score	0.8781982660293579
keywords[0].display_name	Prostatectomy
keywords[1].id	https://openalex.org/keywords/medicine
keywords[1].score	0.819034218788147
keywords[1].display_name	Medicine
keywords[2].id	https://openalex.org/keywords/prostate-cancer
keywords[2].score	0.7864266633987427
keywords[2].display_name	Prostate cancer
keywords[3].id	https://openalex.org/keywords/gynecology
keywords[3].score	0.5157954692840576
keywords[3].display_name	Gynecology
keywords[4].id	https://openalex.org/keywords/prostate-specific-antigen
keywords[4].score	0.4469529390335083
keywords[4].display_name	Prostate-specific antigen
keywords[5].id	https://openalex.org/keywords/urology
keywords[5].score	0.3888070285320282
keywords[5].display_name	Urology
keywords[6].id	https://openalex.org/keywords/general-surgery
keywords[6].score	0.3578466773033142
keywords[6].display_name	General surgery
keywords[7].id	https://openalex.org/keywords/cancer
keywords[7].score	0.3353397846221924
keywords[7].display_name	Cancer
keywords[8].id	https://openalex.org/keywords/internal-medicine
keywords[8].score	0.2792052626609802
keywords[8].display_name	Internal medicine
language	en
locations[0].id	doi:10.1016/j.juro.2016.02.662
locations[0].is_oa	True
locations[0].source.id	https://openalex.org/S30525748
locations[0].source.issn	0022-5347, 1527-3792
locations[0].source.type	journal
locations[0].source.is_oa	False
locations[0].source.issn_l	0022-5347
locations[0].source.is_core	True
locations[0].source.is_in_doaj	False
locations[0].source.display_name	The Journal of Urology
locations[0].source.host_organization	https://openalex.org/P4310315671
locations[0].source.host_organization_name	Lippincott Williams & Wilkins
locations[0].source.host_organization_lineage	https://openalex.org/P4310315671
locations[0].license
locations[0].pdf_url	https://www.auajournals.org/doi/pdf/10.1016/j.juro.2016.02.662
locations[0].version	publishedVersion
locations[0].raw_type	journal-article
locations[0].license_id
locations[0].is_accepted	True
locations[0].is_published	True
locations[0].raw_source_name	Journal of Urology
locations[0].landing_page_url	https://doi.org/10.1016/j.juro.2016.02.662
indexed_in	crossref
authorships[0].author.id	https://openalex.org/A5067252578
authorships[0].author.orcid	https://orcid.org/0000-0001-8586-784X
authorships[0].author.display_name	Takahiro Inoue
authorships[0].affiliations[0].raw_affiliation_string	Kyoto, Japan
authorships[0].author_position	first
authorships[0].raw_author_name	Takahiro Inoue
authorships[0].is_corresponding	False
authorships[0].raw_affiliation_strings	Kyoto, Japan
authorships[1].author.id	https://openalex.org/A5064270351
authorships[1].author.orcid	https://orcid.org/0000-0002-1273-5288
authorships[1].author.display_name	Kei Mizuno
authorships[1].affiliations[0].raw_affiliation_string	Otsu, Japan
authorships[1].author_position	middle
authorships[1].raw_author_name	Kei Mizuno
authorships[1].is_corresponding	False
authorships[1].raw_affiliation_strings	Otsu, Japan
authorships[2].author.id	https://openalex.org/A5082935375
authorships[2].author.orcid	https://orcid.org/0000-0002-6481-1967
authorships[2].author.display_name	Hidefumi Kinoshita
authorships[2].affiliations[0].raw_affiliation_string	Hirakata, Japan
authorships[2].author_position	middle
authorships[2].raw_author_name	Hidefumi Kinoshita
authorships[2].is_corresponding	False
authorships[2].raw_affiliation_strings	Hirakata, Japan
authorships[3].author.id	https://openalex.org/A5113570041
authorships[3].author.orcid
authorships[3].author.display_name	Toshifumi Yano
authorships[3].affiliations[0].raw_affiliation_string	Kobe, Japan
authorships[3].author_position	middle
authorships[3].raw_author_name	Toshifumi Yano
authorships[3].is_corresponding	False
authorships[3].raw_affiliation_strings	Kobe, Japan
authorships[4].author.id	https://openalex.org/A5013917805
authorships[4].author.orcid	https://orcid.org/0009-0004-0955-5683
authorships[4].author.display_name	Hiroaki Kawanishi
authorships[4].affiliations[0].raw_affiliation_string	Tenri, Japan
authorships[4].author_position	middle
authorships[4].raw_author_name	Hiroaki Kawanishi
authorships[4].is_corresponding	False
authorships[4].raw_affiliation_strings	Tenri, Japan
authorships[5].author.id	https://openalex.org/A5045312589
authorships[5].author.orcid
authorships[5].author.display_name	Hideki Kanda
authorships[5].affiliations[0].raw_affiliation_string	Tsu, Japan
authorships[5].author_position	middle
authorships[5].raw_author_name	Hideki Kanda
authorships[5].is_corresponding	False
authorships[5].raw_affiliation_strings	Tsu, Japan
authorships[6].author.id	https://openalex.org/A5029066320
authorships[6].author.orcid	https://orcid.org/0000-0002-3591-1715
authorships[6].author.display_name	Naoki Terada
authorships[6].affiliations[0].raw_affiliation_string	Kyoto, Japan
authorships[6].author_position	middle
authorships[6].raw_author_name	Naoki Terada
authorships[6].is_corresponding	False
authorships[6].raw_affiliation_strings	Kyoto, Japan
authorships[7].author.id	https://openalex.org/A5075102109
authorships[7].author.orcid	https://orcid.org/0000-0002-5255-6479
authorships[7].author.display_name	Tomomi Kamba
authorships[7].affiliations[0].raw_affiliation_string	Kyoto, Japan
authorships[7].author_position	middle
authorships[7].raw_author_name	Tomomi Kamba
authorships[7].is_corresponding	False
authorships[7].raw_affiliation_strings	Kyoto, Japan
authorships[8].author.id	https://openalex.org/A5036381262
authorships[8].author.orcid	https://orcid.org/0000-0002-4980-3125
authorships[8].author.display_name	Kazuhiro Okumura
authorships[8].affiliations[0].raw_affiliation_string	Tenri, Japan
authorships[8].author_position	middle
authorships[8].raw_author_name	Kazuhiro Okumura
authorships[8].is_corresponding	False
authorships[8].raw_affiliation_strings	Tenri, Japan
authorships[9].author.id	https://openalex.org/A5039335186
authorships[9].author.orcid	https://orcid.org/0009-0003-2494-0355
authorships[9].author.display_name	Mutsushi Kawakita
authorships[9].affiliations[0].raw_affiliation_string	Kobe, Japan
authorships[9].author_position	middle
authorships[9].raw_author_name	Mutsushi Kawakita
authorships[9].is_corresponding	False
authorships[9].raw_affiliation_strings	Kobe, Japan
authorships[10].author.id	https://openalex.org/A5112815083
authorships[10].author.orcid
authorships[10].author.display_name	Keiji Ogura
authorships[10].affiliations[0].raw_affiliation_string	Otsu, Japan
authorships[10].author_position	middle
authorships[10].raw_author_name	Keiji Ogura
authorships[10].is_corresponding	False
authorships[10].raw_affiliation_strings	Otsu, Japan
authorships[11].author.id	https://openalex.org/A5079563340
authorships[11].author.orcid	https://orcid.org/0000-0003-0516-9246
authorships[11].author.display_name	Yoshiki Sugimura
authorships[11].affiliations[0].raw_affiliation_string	Tsu, Japan
authorships[11].author_position	middle
authorships[11].raw_author_name	Yoshiki Sugimura
authorships[11].is_corresponding	False
authorships[11].raw_affiliation_strings	Tsu, Japan
authorships[12].author.id	https://openalex.org/A5001837870
authorships[12].author.orcid	https://orcid.org/0000-0003-0973-1478
authorships[12].author.display_name	Tadashi Matsuda
authorships[12].affiliations[0].raw_affiliation_string	Hirakata, Japan
authorships[12].author_position	middle
authorships[12].raw_author_name	Tadashi Matsuda
authorships[12].is_corresponding	False
authorships[12].raw_affiliation_strings	Hirakata, Japan
authorships[13].author.id	https://openalex.org/A5083025134
authorships[13].author.orcid	https://orcid.org/0000-0003-3651-5455
authorships[13].author.display_name	Osamu Ogawa
authorships[13].affiliations[0].raw_affiliation_string	Kyoto, Japan
authorships[13].author_position	last
authorships[13].raw_author_name	Osamu Ogawa
authorships[13].is_corresponding	False
authorships[13].raw_affiliation_strings	Kyoto, Japan
has_content.pdf	True
has_content.grobid_xml	True
is_paratext	False
open_access.is_oa	True
open_access.oa_url	https://www.auajournals.org/doi/pdf/10.1016/j.juro.2016.02.662
open_access.oa_status	bronze
open_access.any_repository_has_fulltext	False
created_date	2025-10-10T00:00:00
display_name	MP57-08 PROSTATE-SPECIFIC ANTIGEN DENSITY IS THE MOST APPROPRIATE FACTOR FOR DETECTING UNFAVORABLE PATHOLOGY AFTER RADICAL PROSTATECTOMY IN MEN ELIGIBLE FOR ACTIVE SURVEILLANCE FROM MUTLI-INSTITUTIONAL STUDY
has_fulltext	True
is_retracted	False
updated_date	2025-11-06T03:46:38.306776
primary_topic.id	https://openalex.org/T10124
primary_topic.field.id	https://openalex.org/fields/27
primary_topic.field.display_name	Medicine
primary_topic.score	0.9839000105857849
primary_topic.domain.id	https://openalex.org/domains/4
primary_topic.domain.display_name	Health Sciences
primary_topic.subfield.id	https://openalex.org/subfields/2740
primary_topic.subfield.display_name	Pulmonary and Respiratory Medicine
primary_topic.display_name	Prostate Cancer Diagnosis and Treatment
related_works	https://openalex.org/W4255881101, https://openalex.org/W2030383011, https://openalex.org/W2023475404, https://openalex.org/W4230379269, https://openalex.org/W2080763436, https://openalex.org/W42639213, https://openalex.org/W2741499688, https://openalex.org/W2032157250, https://openalex.org/W1888477076, https://openalex.org/W1988513079
cited_by_count	0
locations_count	1
best_oa_location.id	doi:10.1016/j.juro.2016.02.662
best_oa_location.is_oa	True
best_oa_location.source.id	https://openalex.org/S30525748
best_oa_location.source.issn	0022-5347, 1527-3792
best_oa_location.source.type	journal
best_oa_location.source.is_oa	False
best_oa_location.source.issn_l	0022-5347
best_oa_location.source.is_core	True
best_oa_location.source.is_in_doaj	False
best_oa_location.source.display_name	The Journal of Urology
best_oa_location.source.host_organization	https://openalex.org/P4310315671
best_oa_location.source.host_organization_name	Lippincott Williams & Wilkins
best_oa_location.source.host_organization_lineage	https://openalex.org/P4310315671
best_oa_location.license
best_oa_location.pdf_url	https://www.auajournals.org/doi/pdf/10.1016/j.juro.2016.02.662
best_oa_location.version	publishedVersion
best_oa_location.raw_type	journal-article
best_oa_location.license_id
best_oa_location.is_accepted	True
best_oa_location.is_published	True
best_oa_location.raw_source_name	Journal of Urology
best_oa_location.landing_page_url	https://doi.org/10.1016/j.juro.2016.02.662
primary_location.id	doi:10.1016/j.juro.2016.02.662
primary_location.is_oa	True
primary_location.source.id	https://openalex.org/S30525748
primary_location.source.issn	0022-5347, 1527-3792
primary_location.source.type	journal
primary_location.source.is_oa	False
primary_location.source.issn_l	0022-5347
primary_location.source.is_core	True
primary_location.source.is_in_doaj	False
primary_location.source.display_name	The Journal of Urology
primary_location.source.host_organization	https://openalex.org/P4310315671
primary_location.source.host_organization_name	Lippincott Williams & Wilkins
primary_location.source.host_organization_lineage	https://openalex.org/P4310315671
primary_location.license
primary_location.pdf_url	https://www.auajournals.org/doi/pdf/10.1016/j.juro.2016.02.662
primary_location.version	publishedVersion
primary_location.raw_type	journal-article
primary_location.license_id
primary_location.is_accepted	True
primary_location.is_published	True
primary_location.raw_source_name	Journal of Urology
primary_location.landing_page_url	https://doi.org/10.1016/j.juro.2016.02.662
publication_date	2016-03-28
publication_year	2016
referenced_works_count	0
abstract_inverted_index.&	568
abstract_inverted_index.,	73, 82, 91, 100, 109, 118, 127, 136, 145, 154, 163, 172, 181
abstract_inverted_index.2	338
abstract_inverted_index.=	405, 420, 449, 456, 481, 494
abstract_inverted_index.P	448, 455
abstract_inverted_index.(P	404, 419, 480, 493
abstract_inverted_index.10	330, 465
abstract_inverted_index.42	366
abstract_inverted_index.6,	335
abstract_inverted_index.AS	282, 319
abstract_inverted_index.IN	27
abstract_inverted_index.IS	15
abstract_inverted_index.Of	313
abstract_inverted_index.On	387
abstract_inverted_index.RP	272, 290, 302, 545
abstract_inverted_index.We	241
abstract_inverted_index.an	223
abstract_inverted_index.as	222, 260, 278
abstract_inverted_index.at	303
abstract_inverted_index.by	70, 79, 88, 97, 106, 115, 124, 133, 142, 151, 160, 169, 178, 188, 284, 576, 583, 590, 597, 604, 611, 618, 625, 632, 639, 646, 653, 660, 667
abstract_inverted_index.in	234, 281
abstract_inverted_index.is	238
abstract_inverted_index.of	3, 206, 289, 297, 384, 394, 427, 461, 477, 490, 500, 520, 544, 551, 553
abstract_inverted_index.or	250, 271, 466
abstract_inverted_index.to	196, 225, 311
abstract_inverted_index.©	559
abstract_inverted_index....	676
abstract_inverted_index.167	360
abstract_inverted_index.306	316
abstract_inverted_index.7),	258
abstract_inverted_index.AND	203
abstract_inverted_index.AS.	529
abstract_inverted_index.All	192, 671
abstract_inverted_index.Apr	10
abstract_inverted_index.FOR	20, 30
abstract_inverted_index.Kei	38, 74, 579
abstract_inverted_index.MEN	28
abstract_inverted_index.PDF	674
abstract_inverted_index.PSA	328, 377
abstract_inverted_index.RP.	356
abstract_inverted_index.THE	16
abstract_inverted_index.The	293, 341, 425
abstract_inverted_index.You	0
abstract_inverted_index.and	62, 182, 262, 336, 349, 352, 365, 380, 382, 392, 408, 411, 413, 422, 429, 451, 472, 483, 502
abstract_inverted_index.are	523
abstract_inverted_index.but	231
abstract_inverted_index.for	228, 528
abstract_inverted_index.had	368
abstract_inverted_index.has	220
abstract_inverted_index.low	207
abstract_inverted_index.men	299
abstract_inverted_index.met	317
abstract_inverted_index.not	212
abstract_inverted_index.pT3	270
abstract_inverted_index.six	304
abstract_inverted_index.the	232, 286, 318, 443, 462, 498, 516, 535, 557
abstract_inverted_index.vs.	446, 453
abstract_inverted_index.was	432, 488, 505, 533
abstract_inverted_index.who	300
abstract_inverted_index.≤	329, 334, 337
abstract_inverted_index.≥	257, 269, 275
abstract_inverted_index.(AS)	219
abstract_inverted_index.(RP)	254
abstract_inverted_index.(≥	248
abstract_inverted_index.1753	298
abstract_inverted_index.2005	310
abstract_inverted_index.4+3,	276
abstract_inverted_index.FROM	33
abstract_inverted_index.III1	9
abstract_inverted_index.MOST	17
abstract_inverted_index.More	68, 77, 86, 95, 104, 113, 122, 131, 140, 149, 158, 167, 176, 186, 574, 581, 588, 595, 602, 609, 616, 623, 630, 637, 644, 651, 658, 665
abstract_inverted_index.Most	205
abstract_inverted_index.PPCs	414, 473
abstract_inverted_index.PSA,	376
abstract_inverted_index.PSAD	391, 412, 471, 487, 532
abstract_inverted_index.View	191
abstract_inverted_index.Yano	94, 594
abstract_inverted_index.age,	375, 390
abstract_inverted_index.also	263
abstract_inverted_index.and,	486
abstract_inverted_index.even	547
abstract_inverted_index.from	309
abstract_inverted_index.have	1
abstract_inverted_index.high	306
abstract_inverted_index.less	438, 511
abstract_inverted_index.men,	230
abstract_inverted_index.more	467
abstract_inverted_index.most	536
abstract_inverted_index.pT3)	249
abstract_inverted_index.rate	426, 499
abstract_inverted_index.risk	208
abstract_inverted_index.than	439, 442, 512, 515
abstract_inverted_index.that	245, 265, 321, 489
abstract_inverted_index.this	71, 80, 89, 98, 107, 116, 125, 134, 143, 152, 161, 170, 179, 189, 577, 584, 591, 598, 605, 612, 619, 626, 633, 640, 647, 654, 661, 668
abstract_inverted_index.were	344, 398, 415, 474
abstract_inverted_index.when	525
abstract_inverted_index.with	348, 401, 416, 437, 464, 510, 540
abstract_inverted_index.0.004	450
abstract_inverted_index.0.016	482
abstract_inverted_index.2011.	312
abstract_inverted_index.27.8%	452
abstract_inverted_index.AFTER	24
abstract_inverted_index.Among	358
abstract_inverted_index.Inoue	67, 573
abstract_inverted_index.Kamba	130, 622
abstract_inverted_index.Kanda	112, 608
abstract_inverted_index.Keiji	56, 155, 642
abstract_inverted_index.Naoki	48, 119, 614
abstract_inverted_index.Ogawa	64, 185, 664
abstract_inverted_index.Ogura	157, 643
abstract_inverted_index.Osamu	63, 183, 663
abstract_inverted_index.STUDY	35
abstract_inverted_index.Yano,	43
abstract_inverted_index.after	355
abstract_inverted_index.among	435, 508, 556
abstract_inverted_index.cases	463
abstract_inverted_index.cores	396, 469, 522
abstract_inverted_index.score	256, 274, 333
abstract_inverted_index.serum	327
abstract_inverted_index.stage	268, 324
abstract_inverted_index.still	239, 534
abstract_inverted_index.study	295
abstract_inverted_index.them,	359
abstract_inverted_index.these	314
abstract_inverted_index.those	229
abstract_inverted_index.under	548
abstract_inverted_index.would	211
abstract_inverted_index.(63.2%	445
abstract_inverted_index.(PPCs)	397
abstract_inverted_index.0.0006	407
abstract_inverted_index.0.0030	421
abstract_inverted_index.0.007,	457
abstract_inverted_index.0.047,	423
abstract_inverted_index.14.9%,	454
abstract_inverted_index.46.6%,	447
abstract_inverted_index.ACTIVE	31
abstract_inverted_index.Active	217
abstract_inverted_index.Author	193
abstract_inverted_index.Expand	670
abstract_inverted_index.FACTOR	19
abstract_inverted_index.Hideki	46, 110, 607
abstract_inverted_index.Inoue,	37
abstract_inverted_index.Kamba,	51
abstract_inverted_index.Kanda,	47
abstract_inverted_index.Mizuno	76, 580
abstract_inverted_index.Ogura,	57
abstract_inverted_index.T1c/T2	325
abstract_inverted_index.Terada	121, 615
abstract_inverted_index.Tomomi	50, 128, 621
abstract_inverted_index.Volume	561
abstract_inverted_index.author	72, 81, 90, 99, 108, 117, 126, 135, 144, 153, 162, 171, 180, 190, 578, 585, 592, 599, 606, 613, 620, 627, 634, 641, 648, 655, 662, 669
abstract_inverted_index.become	213
abstract_inverted_index.biopsy	441, 468, 514, 521
abstract_inverted_index.cancer	210
abstract_inverted_index.cores.	340, 386
abstract_inverted_index.detect	266
abstract_inverted_index.during	215
abstract_inverted_index.factor	538
abstract_inverted_index.higher	434, 507
abstract_inverted_index.needed	524
abstract_inverted_index.ng/ml,	331
abstract_inverted_index.number	381, 519
abstract_inverted_index.others	444
abstract_inverted_index.volume	307, 555
abstract_inverted_index.(13.7%)	367
abstract_inverted_index.(54.6%)	361
abstract_inverted_index.(PSAD),	379
abstract_inverted_index.0.0001,	409
abstract_inverted_index.0.0033,	406
abstract_inverted_index.0.0084,	484
abstract_inverted_index.0.034).	495
abstract_inverted_index.10-core	440, 513
abstract_inverted_index.4SApril	563
abstract_inverted_index.ANTIGEN	13
abstract_inverted_index.Because	497
abstract_inverted_index.Cancer:	5
abstract_inverted_index.DENSITY	14
abstract_inverted_index.Gleason	255, 273, 332
abstract_inverted_index.Hiroaki	44, 101, 600
abstract_inverted_index.InEmail	201
abstract_inverted_index.METHODS	292
abstract_inverted_index.Matsuda	175, 657
abstract_inverted_index.Mizuno,	39
abstract_inverted_index.Okumura	139, 629
abstract_inverted_index.RADICAL	25
abstract_inverted_index.RESULTS	357
abstract_inverted_index.Tadashi	60, 173, 656
abstract_inverted_index.Terada,	49
abstract_inverted_index.Therapy	8
abstract_inverted_index.Yoshiki	58, 164, 649
abstract_inverted_index.adverse	369, 417, 430, 491, 503
abstract_inverted_index.between	346
abstract_inverted_index.centers	308
abstract_inverted_index.defined	259, 277
abstract_inverted_index.density	378
abstract_inverted_index.disease	363, 402, 478
abstract_inverted_index.emerged	221
abstract_inverted_index.factors	244, 264, 476
abstract_inverted_index.feature	543
abstract_inverted_index.methods	550
abstract_inverted_index.others,	517
abstract_inverted_index.predict	246
abstract_inverted_index.without	350
abstract_inverted_index.(radical	252
abstract_inverted_index.195Issue	562
abstract_inverted_index.ELIGIBLE	29
abstract_inverted_index.Hidefumi	40, 83, 586
abstract_inverted_index.Kawakita	148, 636
abstract_inverted_index.Kazuhiro	52, 137, 628
abstract_inverted_index.Matsuda,	61
abstract_inverted_index.Mutsushi	54, 146, 635
abstract_inverted_index.Okumura,	53
abstract_inverted_index.Sugimura	166, 650
abstract_inverted_index.Surgical	7
abstract_inverted_index.Takahiro	36, 65, 572
abstract_inverted_index.ToolsAdd	195
abstract_inverted_index.analysis	460
abstract_inverted_index.analyzed	242
abstract_inverted_index.articles	69, 78, 87, 96, 105, 114, 123, 132, 141, 150, 159, 168, 177, 187, 575, 582, 589, 596, 603, 610, 617, 624, 631, 638, 645, 652, 659, 666
abstract_inverted_index.clinical	323
abstract_inverted_index.compared	345
abstract_inverted_index.criteria	320
abstract_inverted_index.defining	235
abstract_inverted_index.disease,	326
abstract_inverted_index.features	343
abstract_inverted_index.findings	288
abstract_inverted_index.included	322, 374
abstract_inverted_index.lacking.	240
abstract_inverted_index.patients	347, 436, 509
abstract_inverted_index.positive	339, 385, 395
abstract_inverted_index.prostate	209, 554
abstract_inverted_index.required	362
abstract_inverted_index.revealed	470
abstract_inverted_index.2016Page:	564
abstract_inverted_index.Copyright	567
abstract_inverted_index.DETECTING	21
abstract_inverted_index.Kawakita,	55
abstract_inverted_index.Kawanishi	103, 601
abstract_inverted_index.Kinoshita	85, 587
abstract_inverted_index.MizunoKei	75
abstract_inverted_index.PATHOLOGY	23
abstract_inverted_index.Sugimura,	59
abstract_inverted_index.Toshifumi	42, 92, 593
abstract_inverted_index.analysis,	389
abstract_inverted_index.consensus	233
abstract_inverted_index.consisted	296
abstract_inverted_index.different	549
abstract_inverted_index.e755-e756	565
abstract_inverted_index.evaluated	373
abstract_inverted_index.examining	285
abstract_inverted_index.immediate	226
abstract_inverted_index.important	537
abstract_inverted_index.lifetime.	216
abstract_inverted_index.pathology	418, 431, 492, 504
abstract_inverted_index.patients,	315
abstract_inverted_index.selecting	526
abstract_inverted_index.specimens	546
abstract_inverted_index.treatment	227
abstract_inverted_index.underwent	301
abstract_inverted_index.upgrading	251
abstract_inverted_index.upstaging	247
abstract_inverted_index.Kawanishi,	45
abstract_inverted_index.Kinoshita,	41
abstract_inverted_index.Localized:	6
abstract_inverted_index.OBJECTIVES	204
abstract_inverted_index.OgawaOsamu	184
abstract_inverted_index.OguraKeiji	156
abstract_inverted_index.associated	400, 539
abstract_inverted_index.candidates	237, 283, 527
abstract_inverted_index.parameters	372
abstract_inverted_index.pathology.	370
abstract_inverted_index.percentage	383, 393
abstract_inverted_index.specimens.	291
abstract_inverted_index.′adverse	279, 353
abstract_inverted_index.2016MP57-08	11
abstract_inverted_index.APPROPRIATE	18
abstract_inverted_index.CONCLUSIONS	496
abstract_inverted_index.Information	571
abstract_inverted_index.KambaTomomi	129
abstract_inverted_index.KandaHideki	111
abstract_inverted_index.TeradaNaoki	120
abstract_inverted_index.UNFAVORABLE	22
abstract_inverted_index.alternative	224
abstract_inverted_index.appropriate	236, 518
abstract_inverted_index.examination	552
abstract_inverted_index.independent	305
abstract_inverted_index.significant	475
abstract_inverted_index.unfavorable	541
abstract_inverted_index.Furthermore,	530
abstract_inverted_index.INTRODUCTION	202
abstract_inverted_index.Multivariate	459
abstract_inverted_index.Preoperative	371
abstract_inverted_index.SURVEILLANCE	32
abstract_inverted_index.multivariate	388
abstract_inverted_index.pathological	267, 287, 542
abstract_inverted_index.pathology′	280, 354
abstract_inverted_index.preoperative	243, 531
abstract_inverted_index.surveillance	218
abstract_inverted_index.Advertisement	566, 672, 673
abstract_inverted_index.InoueTakahiro	66
abstract_inverted_index.PROSTATECTOMY	26
abstract_inverted_index.Permissions©	569
abstract_inverted_index.YanoToshifumi	93
abstract_inverted_index.accessJournal	2
abstract_inverted_index.independently	399
abstract_inverted_index.institutions.	558
abstract_inverted_index.prostatectomy	253
abstract_inverted_index.retrospective	294
abstract_inverted_index.significantly	433, 506
abstract_inverted_index.CitationsTrack	198
abstract_inverted_index.MatsudaTadashi	174
abstract_inverted_index.respectively),	410, 485
abstract_inverted_index.respectively).	424, 458
abstract_inverted_index.OkumuraKazuhiro	138
abstract_inverted_index.SugimuraYoshiki	165
abstract_inverted_index.UrologyProstate	4
abstract_inverted_index.downloadLoading	675
abstract_inverted_index.KawakitaMutsushi	147
abstract_inverted_index.KawanishiHiroaki	102
abstract_inverted_index.life-threatening	214
abstract_inverted_index.reclassification	403, 428, 479, 501
abstract_inverted_index.2016MetricsAuthor	570
abstract_inverted_index.KinoshitaHidefumi	84
abstract_inverted_index.PROSTATE-SPECIFIC	12
abstract_inverted_index.favoritesDownload	197
abstract_inverted_index.reclassification,	364
abstract_inverted_index.MUTLI-INSTITUTIONAL	34
abstract_inverted_index.clinic-pathological	342
abstract_inverted_index.′reclassification′	351
abstract_inverted_index.′reclassification′,	261
abstract_inverted_index.ShareFacebookTwitterLinked	200
abstract_inverted_index.CitationsPermissionsReprints	199
abstract_inverted_index.2016FiguresReferencesRelatedDetails	560
abstract_inverted_index.Informationhttps://doi.org/10.1016/j.juro.2016.02.662AboutPDF	194
cited_by_percentile_year
countries_distinct_count	0
institutions_distinct_count	14
citation_normalized_percentile.value	0.02207691
citation_normalized_percentile.is_in_top_1_percent	False
citation_normalized_percentile.is_in_top_10_percent	False